Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Tadekinig alfa (Primary)
- Indications Autoimmune disorders
- Focus Registrational; Therapeutic Use
- Sponsors AB2 Bio
- 23 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
- 23 Jan 2019 Planned primary completion date changed from 1 May 2019 to 1 Nov 2019.
- 31 Aug 2018 Biomarkers information updated